Mevion Installs Breakthrough Proton Pencil Beam Scanning Technology at MedStar Georgetown University Hospital

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

April 4, 2017

Mevion Medical Systems announces the installation of the first MEVION S250i with HYPERSCAN, Mevion’s advanced proton therapy pencil beam scanning system, at MedStar Georgetown University Hospital.

Mevion Medical says this breakthrough technology will allow MedStar Georgetown to deliver a new standard of Intensity Modulated Proton Therapy (IMPT) combining the fastest energy modulation with the sharpest lateral penumbra improving the treatment options available to cancer patients.

This is the first installation of HYPERSCAN with Adaptive Aperture, Mevion’s novel proton multi-leaf collimator. The installation at MedStar Georgetown will be followed by a MEVION S250i installation at Zuidoost Nederland Protonen Therapie Centrum, co-located at the Maastricht Clinic, in the Netherlands and at the Ackerman Cancer Center in Jacksonville, Florida, which will be the second unit installed at the private, physician-run center.

“Mevion is proud to be working with MedStar Georgetown to achieve this milestone, and to be making proton therapy accessible to the Washington D.C. area. HYPERSCAN with Adaptive Aperture represents a real paradigm shift for the entire industry. This is the only proton system able to precisely shape each energy layer and deliver those layers at speeds up to 50 times faster than other systems. The results are highly conformal proton dose distributions that can be automatically adapted as treatment progresses,” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems.

The Adaptive Aperture is a proprietary low-profile micro-multi-leaf collimator system designed specifically for HYPERSCAN pencil beam scanning. It eliminates the need for manual apertures and adjustments because its unique layer-by-layer beam collimation achieves unprecedented one to three millimeter collimated effective spot sizes for all energies. HYPERSCAN with Adaptive Aperture is capable of scanning a typical lung tumor in less than two seconds – eliminating many of the challenges caused by patient motion that other pencil beam scanning systems encounter.

Proton therapy provides targeted radiation treatment for many types of cancer, significantly reducing the dose of radiation to healthy tissue by as much as a factor of three, while still maintaining high conformance to the treatment target. Mevion developed the world’s first compact proton therapy system to help increase access to this valuable therapy and currently has more compact systems under contract, installed and treating patients than any other proton therapy manufacturer.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.